TAIAN CITY,
Experts from the bio-pharmaceutical industry included Mr.
The forum provided a platform for industry experts to discuss and provide advice to the Company that could create synergies among its subsidiaries including, the initiation of research and development of new drugs, efficient use of resources among the subsidiaries, quality control procedures during collection, production and distribution processes, and other expert opinions to create long term, sustainable growth for the Company.
"The forum has provided us with many strategic ideas to further the growth
of the new China Biologic," said Mr.
About China Biologic Products, Inc.
China Biologic Products, Inc. (the "Company"), through its indirect
majority-owned subsidiaries, Shandong Taibang Biological Products Co. Ltd. and
Chongqing Dalin Biologic Technologies Co., Ltd, and its equity investment in
Xi'an Huitian Blood Products Co., Ltd., is currently the largest
non-state-owned plasma-based biopharmaceutical company approved by the Chinese
government. The Company is a fully integrated biologic products company with
plasma collection, production and manufacturing, research and development, and
commercial operations. The Company's blood products are irreplaceable during
medical emergencies, and are used for the prevention and treatment of various
diseases. It sells its plasma-based biopharmaceutical products to hospitals
and other healthcare facilities in
Safe Harbor Statement
This release may contain certain "forward-looking statements" relating to the business of China Biologic Products, Inc. and its subsidiary companies. All statements, other than statements of historical fact included herein are "forward-looking statements," including statements regarding: the impact of the Company's forum for strategy and development on the business and operations of the Company, including the ability of the Company to create synergies among its subsidiaries; the ability of the Company to achieve its commercial objectives; the business strategy, plans and objectives of the Company and its subsidiaries; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward- looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
For more information, please contact: Company Contact: Mr. Y. Tristan Kuo Chief Financial Officer China Biologic Products, Inc. Tel: +86-538-6202206 Email: IR@chinabiologic.com Web: http://www.chinabiologic.com Investor Relations Contact: Mr. Crocker Coulson, President CCG Investor Relations Tel: +1-646-213-1915 (NY office) or Mr. Gary Chin Tel: +1-646-213-1909 Email: crocker.coulson@ccgir.com Web: http://www.ccgirasia.com
SOURCE China Biologic Products, Inc.